<DOC>
	<DOC>NCT00746681</DOC>
	<brief_summary>Tolterodine is approved for use in the treatment of overactive bladder (OAB). The study is designed to a investigate whether pregabalin may have efficacy in OAB and whether the efficacy is altered when it is combined with tolterodine.</brief_summary>
	<brief_title>Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Women &gt; 18 years Old Diagnosis of OAB (micturition frequency &gt;/= 8 times per day; urinary urgency &gt;/= 4 times per week) Subjects with symptoms of overactive bladder for less than 6 months prior to randomization. Significant stress incontinence as determined by the investigator e.g. stress predominant mixed incontinence, positive cough provocation test. Subjects with any condition that would contraindicate the use of tolterodine or pregabalin, including: Uncontrolled narrow angle glaucoma; Urinary retention; Myasthenia gravis; Gastric retention; Severe ulcerative colitis; Toxic megacolon; Rare hereditary problems of galactose intolerance; Fructose intolerance; Sucroseisomalate insufficiency; Lapp lactase deficiency; Glucosegalactose malabsorption.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>